BridgeBio Pharma has transferred several preclinical and early clinical-stage drugs to a new company, GondolaBio, that’s drawn $300 million in promised investment from a syndicate of blue-chip life sciences investors.

BridgeBio Pharma已将几种临床前和早期临床阶段药物转让给一家新公司GondolaBio，该公司已从蓝筹股生命科学投资者财团获得3亿美元的承诺投资。

Viking Global Investors, Patient Square Capital and Frazier Life Sciences are among the investors backing GondolaBio, according to a Wednesday securities filing from BridgeBio. Also involved is an entity owned by BridgeBio CEO Neil Kumar.

根据BridgeBio周三提交的证券文件，维京全球投资者、Patient Square Capital和Frazier Life Sciences是支持GondolaBio的投资者之一。BridgeBio首席执行官尼尔·库马尔（Neil Kumar）拥有的一家实体也参与其中。

The Palo Alto, California biotechnology company will initially hold a 45% stake in GondolaBio, although that will go down as additional capital commitments are funded. The new company will inherit drug programs aimed at the rare diseases erythropoietic protoporphyria, alpha-1 antitrypsin deficiency and tuberous sclerosis complex..

加利福尼亚州帕洛阿尔托的生物技术公司最初将持有贡多拉比奥45%的股份，尽管随着额外的资本承诺得到资助，这一比例将下降。新公司将继承针对罕见疾病红细胞生成性原卟啉症、α-1抗胰蛋白酶缺乏症和结节性硬化症的药物计划。。

BridgeBio has already slimmed its pipeline down once this year, spinning out a slate of experimental cancer drugs into a new company called BridgeBio Oncology Therapeutics. The company has long operated on a “hub-and-spoke” model, functioning as a parent for biotech subsidiaries. It previously launched QED Therapeutics and Adrenas Therapeutics, and several years ago reacquired another, Eidos Therapeutics, that it formed in 2017..

BridgeBio今年已经缩减了其生产线，将一系列实验性抗癌药物拆分为一家名为BridgeBio Oncology Therapeutics的新公司。该公司长期以来一直采用“中心辐射”模式，作为生物技术子公司的母公司。它之前推出了QED Therapeutics和Adrenas Therapeutics，几年前又获得了另一款于2017年成立的Eidos Therapeutics。。

The agreement creating GondolaBio was recommended by a committee of “independent and disinterested directors” to BridgeBio’s board, which approved it. The company did not return BioPharma Dive’s request for further information on GondolaBio beyond the details enclosed in the securities filing.

创建贡多拉比的协议是由一个由“独立和无利害关系的董事”组成的委员会向布里奇比奥董事会推荐的，董事会批准了该协议。该公司没有回复BioPharma Dive要求提供更多有关贡多拉比的信息的请求，这些信息超出了证券备案中的细节。

Also committing to invest in GondolaBio are Sequoia Capital, Cormorant Asset Management and Aisling Capital.

红杉资本（Sequoia Capital）、鸬鹚资产管理（Cormorant Asset Management）和艾斯林资本（Aisling Capital）也承诺投资贡多拉比（GondolaBio）。

BridgeBio’s chief asset is a heart drug called acoramidis, which succeeded in Phase 3 testing last year. An approval application is currently under review in the U.S., with a decision expected by late November.

BridgeBio的主要资产是一种名为acoramidis的心脏药物，该药物去年在第三阶段测试中取得了成功。美国目前正在审查批准申请，预计将于11月底做出决定。